| Literature DB >> 27866355 |
John Fayyad1, Nancy A Sampson2, Irving Hwang2, Tomasz Adamowski3, Sergio Aguilar-Gaxiola4, Ali Al-Hamzawi5, Laura H S G Andrade6, Guilherme Borges7, Giovanni de Girolamo8, Silvia Florescu9, Oye Gureje10, Josep Maria Haro11, Chiyi Hu12,13, Elie G Karam14,15,16, Sing Lee17, Fernando Navarro-Mateu18, Siobhan O'Neill19, Beth-Ellen Pennell20, Marina Piazza21,22, José Posada-Villa23, Margreet Ten Have24, Yolanda Torres25, Miguel Xavier26, Alan M Zaslavsky2, Ronald C Kessler2.
Abstract
We previously reported on the cross-national epidemiology of ADHD from the first 10 countries in the WHO World Mental Health (WMH) Surveys. The current report expands those previous findings to the 20 nationally or regionally representative WMH surveys that have now collected data on adult ADHD. The Composite International Diagnostic Interview (CIDI) was administered to 26,744 respondents in these surveys in high-, upper-middle-, and low-/lower-middle-income countries (68.5% mean response rate). Current DSM-IV/CIDI adult ADHD prevalence averaged 2.8% across surveys and was higher in high (3.6%)- and upper-middle (3.0%)- than low-/lower-middle (1.4%)-income countries. Conditional prevalence of current ADHD averaged 57.0% among childhood cases and 41.1% among childhood subthreshold cases. Adult ADHD was significantly related to being male, previously married, and low education. Adult ADHD was highly comorbid with DSM-IV/CIDI anxiety, mood, behavior, and substance disorders and significantly associated with role impairments (days out of role, impaired cognition, and social interactions) when controlling for comorbidities. Treatment seeking was low in all countries and targeted largely to comorbid conditions rather than to ADHD. These results show that adult ADHD is prevalent, seriously impairing, and highly comorbid but vastly under-recognized and undertreated across countries and cultures.Entities:
Keywords: ADHD; Attention-deficit/hyperactivity disorder; Comorbidity; Disability epidemiology; Impairment; Prevalence; Treatment
Mesh:
Year: 2016 PMID: 27866355 PMCID: PMC5325787 DOI: 10.1007/s12402-016-0208-3
Source DB: PubMed Journal: Atten Defic Hyperact Disord ISSN: 1866-6116